...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Vaccine >Evaluation of a vectored equine herpesvirus type 1 (EHV-1) vaccine expressing H3 haemagglutinin in the protection of dogs against canine influenza.
【24h】

Evaluation of a vectored equine herpesvirus type 1 (EHV-1) vaccine expressing H3 haemagglutinin in the protection of dogs against canine influenza.

机译：评估表达H3血凝素的载体马1型疱疹病毒（EHV-1）疫苗在保护犬类抗犬流感中的作用。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

In 2004, canine influenza virus (CIV) was identified as a respiratory pathogen of dogs for the first time and found to be closely related to H3N8 equine influenza virus (EIV). We generated a recombinant vectored vaccine that expresses H3 of a recent isolate of EIV using equine herpesvirus type 1 (EHV-1) as the delivery vehicle. This EHV-1 vectored vaccine exhibited robust and stable EIV H3 expression and induced a strong influenza virus-specific response in both mice and dogs upon intranasal or subcutaneous administration. Furthermore, upon challenge with the recent CIV isolate A/canine/PA/10915-07, protection of vaccinated dogs could be demonstrated by a significant reduction in clinical sings, and, more importantly, by a significant reduction in virus shedding. We concluded that the EHV-1/H3 recombinant vector can be a valuable alternative for protection of dogs against clinical disease induced by CIV and can significantly reduce virus spread.
机译：2004年，犬流感病毒（CIV）首次被鉴定为狗的呼吸道病原体，并被发现与H3N8马流感病毒（EIV）密切相关。我们使用1型马疱疹病毒（EHV-1）作为递送载体，生成了表达EIV最近分离株的H3的重组载体疫苗。这种EHV-1载体疫苗在鼻内或皮下给药后，在小鼠和狗中均表现出稳定且稳定的EIV H3表达，并诱导了强烈的流感病毒特异性应答。此外，在受到最近的CIV分离株A / canine / PA / 10915-07的挑战后，可以通过临床唱歌的显着减少，更重要的是，通过显着减少的病毒脱落来证明对疫苗接种狗的保护。我们得出的结论是，EHV-1 / H3重组载体可以作为保护犬免受CIV诱导的临床疾病的有价值的替代方法，并且可以大大减少病毒的传播。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号